Copyright
©The Author(s) 2022.
World J Stem Cells. Jul 26, 2022; 14(7): 453-472
Published online Jul 26, 2022. doi: 10.4252/wjsc.v14.i7.453
Published online Jul 26, 2022. doi: 10.4252/wjsc.v14.i7.453
Categories | P value | Top five functional annotations | Number of genes |
Carbohydrate Metabolism | 3.50E-20 | Glycolysis of cells | 22 |
Cardiovascular System Development and Function | 3.31E-15 to 4.96E-54 | Angiogenesis, Vasculogenesis, Growth of blood vessel | 84 |
Cell Cycle | 7.42E-16 to 1.82E-38 | Binding of DNA, Cell cycle progression, Interphase, Binding of protein binding site, Arrest in interphase | 99 |
Cell Death and Survival | 3.79E15 to 7.3E-74 | Apoptosis, Necrosis, Cell death of tumor cell lines, Apoptosis of tumor cell lines, Cell viability | 150 |
Cell Morphology | 1.66E-16 to 3.21E-24 | Morphology of tumor cell lines, Tubulation of cells, Transmembrane potential of mitochondria, Cell spreading, Orientation of cells | 77 |
Cell Signaling | 2.83E-19 to 1.1E-26 | Cytokine and chemokine mediated signaling pathway, Quantity of Ca2+ | 48 |
Cell-To-Cell Signaling and Interaction | 3.31E15 to 1.99E-36 | Binding of tumor cell lines, Binding of blood cells, Adhesion of blood cells, Binding of leukocytes, Adhesion of immune cells | 105 |
Cellular Assembly and Organization | 5.56E-16 to 1.42E-17 | Organization of cytoskeleton, Microtubule dynamics, Fibrogenesis | 52 |
Cellular Development | 3.47-15 to 2.85E-73 | Cell proliferation of tumor cell lines, Cell proliferation of carcinoma cell lines, Cell proliferation of breast cancer cell lines, Proliferation of muscle cells, Assembly of cells | 151 |
Cellular Function and Maintenance | 7.07E-32 | Cellular homeostasis | 67 |
Cellular Growth and Proliferation | 9.07E-27 to 2.12E-30 | Proliferation of vascular cells, Colony formation, Proliferation of connective tissue cells, Proliferation of lymphatic system cells, Proliferation of epithelial cells | 101 |
Cellular Movement | 3.31E-15 to 3.35E-67 | Cell movement, Migration of cells, Invasion of cells, Cell movement of tumor cell lines, Migration of tumor cell lines | 132 |
Connective Tissue Development and Function | 1.36E-16 to 1.73E-30 | Growth of connective tissue, Quantity of connective tissue | 46 |
DNA Replication, Recombination, and Repair | 1.67E-18 to 8.06E-31 | Synthesis of DNA, Metabolism of DNA, Degradation of DNA | 47 |
Drug Metabolism, Lipid Metabolism, Small Molecule Biochemistry | 2.36E-16 | Synthesis of prostaglandin E2 | 16 |
Free Radical Scavenging | 6.09E-16 to 5.5E-33 | Synthesis of reactive oxygen species, Production of reactive oxygen species, Generation of reactive oxygen species, Quantity of reactive oxygen species | 43 |
Gene Expression | 1.373-18 to 4.01E-31 | Expression of RNA, Transcription, Transcription of RNA, Transactivation, Transactivation of RNA | 88 |
Inflammatory Response | 5.48E-20 to 2.72E-26 | Inflammation of absolute anatomical region, Inflammation of organ, Inflammatory response, Inflammation of body cavity, Immune response of cells | 77 |
Lipid Metabolism | 6.24E-16 to 9.37E-24 | Synthesis of eicosanoid, Metabolism of eicosanoid, Fatty acid metabolism, Synthesis of fatty acid, Synthesis of prostaglandin | 48 |
Organismal Survival | 9.55E-37 to 2.76E-39 | Organismal death, Survival of organism | 81 |
Post-Translational Modification | 1.86E-18 | Phosphorylation of protein | 34 |
Protein Synthesis | 2.10E-15 | Metabolism of protein | 44 |
Tissue Development | 1.65E-19 to 4.13E-46 | Growth of epithelial tissue, Development of epithelial tissue, Growth of nervous tissue | 62 |
Tissue Morphology | 3.02E-17 to 3.06E-26 | Quantity of cells, Quantity of tumor cell lines | 42 |
Categories | P value | Top five functional annotations | Number of genes |
Carbohydrate Metabolism | 2.45E-12 to 2.81E-17 | Quantity of carbohydrate, Uptake of D-glucose, Synthesis of polysaccharide, Glycolysis, Uptake of monosaccharide | 44 |
Cardiovascular System Development and Function | 1.00E-11 to 8.41E-31 | Angiogenesis, Development of vasculature, Vasculogenesis, Endothelial cell development, Proliferation of endothelial cells | 68 |
Cell Cycle | 6.82E-12 to 4.39E-19 | Mitogenesis, Binding of DNA, Interphase, Arrest in interphase, Cell cycle progression | 53 |
Cell Death and Survival | 1.08E-11 to 5.12E-36 | Cell death of tumor cell lines, Apoptosis of tumor cell lines, Cell viability, Cell survival, Apoptosis | 88 |
Cell Morphology | 1.11E-11 to 4.76E-19 | Tubulation of cells, Morphology of tumor cell lines, Autophagy of cells, Formation of cellular protrusions, Autophagy | 67 |
Cell Signaling | 6.16E-12 to 1.73E-12 | Quantity of Ca2+, Synthesis of nitric oxide | 29 |
Cell-To-Cell Signaling and Interaction | 7.17E-12 to 1.36E-26 | Activation of cells, Interaction of tumor cell lines, Binding of tumor cell lines, Activation of blood cells, Binding of professional phagocytic cells | 62 |
Cell-mediated Immune Response | 4.19E-14 to 7.70E-15 | T cell development, T cell homeostasis | 26 |
Cellular Assembly and Organization | 1.74E-12 to 3.51E-20 | Microtubule dynamics, Organization of cytoskeleton, Organization of cytoplasm, Development of cytoplasm | 52 |
Cellular Development | 1.10E-11 to 2.98E-39 | Cell proliferation of tumor cell lines, Colony formation of cells, Proliferation of smooth muscle cells, Cell proliferation of carcinoma cell lines, Cell proliferation of breast cancer cell lines | 89 |
Cellular Function and Maintenance | 4.81E-13 to 6.37E-27 | Cellular homeostasis, Lymphocyte homeostasis, Function of blood cells | 63 |
Cellular Growth and Proliferation | 8.67E-13 to 3.51E-27 | Colony formation, Proliferation of connective tissue cells, Proliferation of vascular cells, Proliferation of lymphatic system cells, Proliferation of epithelial cells | 72 |
Cellular Movement | 9.45E-12 to 2.99E-30 | Invasion of cells, Cellular infiltration, Cell movement of myeloid cells, Migration of cells, Cell movement of tumor cell lines | 72 |
Connective Tissue Development and Function | 1.56E-16 to 1.63E-25 | Growth of connective tissue, Quantity of connective tissue cells, Quantity of connective tissue, Inflammation of joint, Rheumatic Disease | 50 |
DNA Replication, Recombination, and Repair | 4.08E-22 | Synthesis of DNA | 29 |
Digestive System Development and Function | 1.42E-13 | Morphology of digestive system | 28 |
Embryonic Development | 1.52E-12 to 1.2E-22 | Development of body trunk, Development of abdomen, Growth of embryo, Formation of lymphoid tissue, Formation of lung | 60 |
Free Radical Scavenging | 3.11E-13 to 1.77E-17 | Metabolism of reactive oxygen species, Synthesis of reactive oxygen species, Production of reactive oxygen species | 29 |
Hair and Skin Development and Function | 1.33E-13 | Growth of skin | 17 |
Hematological System Development and Function | 1.17E-11 to 8.08E-21 | Quantity of blood cells, Quantity of leukocytes, Quantity of lymphocytes, Quantity of myeloid cells, Quantity of T lymphocytes | 52 |
Inflammatory Response | 9.18E-22 to 4E-24 | Inflammation of absolute anatomical region, Inflammatory response, Inflammation of body cavity | 59 |
Lipid Metabolism | 8.00E-12 to 3.77E-16 | Concentration of lipid, Synthesis of lipid | 41 |
Lymphoid Tissue Structure and Development | 3.73E-18 | Quantity of lymphatic system cells | 35 |
Molecular Transport | 7.49E-15 | Transport of molecule | 44 |
Nervous System Development and Function | 4.54E-12 | Sensory system development | 22 |
Organ Development, Renal and Urological System Development | 8.50E-12 to 3.25E-12 | Growth of kidney, Growth of renal glomerulus | 11 |
Organ Morphology | 1.78E-13 | Morphology of gland | 22 |
Organismal Development | 1.92E-12 to 7.70E-25 | Morphology of body cavity, Formation of vessel, Morphology of head, Development of genitourinary system, Growth of organism | 73 |
Organismal Survival | 7.68E-26 to 1.24E-28 | Organismal death, Survival of organism | 75 |
Post-Translational Modification | 4.05E-12 to 1.23E-15 | Phosphorylation of protein, Activation of protein | 31 |
Skeletal and Muscular System Development and Function | 1.08E-11 to 1.22E-26 | Morphology of muscle, Function of muscle, Growth of smooth muscle | 39 |
Tissue Development | 1.73E-13 to 3.23E-30 | Development of epithelial tissue, Growth of epithelial tissue, Growth of nervous tissue, Accumulation of cells, Formation of epithelial tissue | 58 |
Tissue Morphology | 3.33E-14 to 2.65E-24 | Quantity of cells, Quantity of progenitor cells | 60 |
Source of MSC | Culture | Hypoxic preconditions, O2%, percentage | Time of exposition | Major findings | Ref. |
Human umbilical-cord | α-Mem deprived of FBS | 1 | 72 h | Proangiogenic effects with an increase in UPAR, angiogenin, VEGF, IGF, Tie-2/TEK and IL-6 expression | [104] |
α-Mem deprived of FBS | 1 | 72 h | Promoted angiogenesis in vitro and in vivo | [103] | |
DMEM/high glucose media with 10% Exo depleted FBS and 1% penicillin/streptomycin | 1 | 48 h | Enhanced of miRNA-126 exerting a pro-angiogenic effect in endothelial cells thereby activating Spred 1/Ras/Erk pathway | [117] | |
α-Mem 10% EV free FBS | 1 | Not defined | EV encapsulated in a hyaluronic acid adhesive hydrogel have angiogenic properties and nerve regeneration effects after traumatic spinal cord injury | [107] | |
Olfactory mucosa | DMEM supplemented with 10% EV-depleted FBS | 3 | 48 h | Promoted angiogenesis via miR-612 transfer | [112] |
Adipose tissue | α-Mem 10% EV free serum | 5 | 48 h | Promoted vessel formation in vitro. Enhanced angiogenesis, neovascularization and graft survival in vivo. Activation of VEGF/VEGF-R | [105,106] |
EV depleted standard medium | 5 | 72 h | Promoted angiogenesis | [32] | |
RPMI medium | 1 | 72 h | Promoted angiogenesis, inhibition of apoptosis, immunomodulation, intracellular ATP recovery and reduction of ROS | [122] | |
Microvascular endothelial cell growth medium 2 media deprived of FBS with supplement of 1× serum | 1 | 24 h | Improved diabetic wound healing. Enhanced fibroblasts proliferation and migration activating PI3K/Akt pathway | [132] | |
DMEM/F12 with 10% EV-free FBS | 0–20 (5 cycles) | Hypoxia 60 min–reoxygenation 30 min | miRNA-224-5p in EV decreases TXNIP expression in cardiomyocytes and protects them from hypoxia mediated injury | [128] | |
Bone marrow | DMEM with low glucose containing inactivated 15% FBS | — | 12 h | Increased of miRNA-21. Synaptic dysfunction restoration, inactivation of STAT3 and NF-kB, reduced plaque deposition and amyloid-β. Regulation of inflammatory responses in APP/PS1 mouse model | [114] |
DMEM with 10% FBS and 1% penicillin-streptomycin | 5 | 6 d | High HMGB1 expression. Activation of JNK pathway and induction of HIF-1α/VEGF expression promoting angiogenesis | [111] | |
Exosome-depleted fetal bovine serum | 1 | 48 h | Increased exosomal levels of miRNA-216a-5p. Inhibition of TLR4/NF-κB and activation of PI3KAKT signaling pathway shifting microglial M1/M2 polarization | [115] | |
α-Mem 10% exosomes-depleted FBS | 2 | 48 h | Promoted angiogenesis | [118] | |
Mesenchymal Stem Cells Medium (Sciencell) 5% exosomes-depleted FBS | 1 | 48 h | Alleviate intervertebral disc degeneration by delivering miR-17-5p | [119] | |
DMEM/F12 10% exosomes-depleted FBS | 3 | 48 h | promote cartilage regeneration via the miR-205–5p/PTEN/AKT pathway | [120] | |
DMEM/F12 10% exosomes-depleted FBS | 5 | 48 h | EV improved chondrocyte proliferation and migration and suppressed chondrocyte apoptosis. miRNA-18-3P/JAK/STAT or miRNA-181c-5p/MAPK signaling pathway may be involved | [121] | |
DMEM low glucose 10% platelet lysate | 1 | 48 h | EV increase angiogenesis, reduced neuronal degeneration, brain atrophy and improved neurological recovery | [116] | |
Murine bone | α-Mem 10% Exo-removed FBS | 0.5 | 24 h | Significant enrichment of miRNA-210. Promoted survival and recovery of cardiac functions. Also, reduced apoptosis and fibrosis and increased the mobilization of cardiac progenitor cells | [124] |
DMEM/F12 supplemented with 10% fetal bovine serum | 1 | 72 h | Overexpression of miR-210 regulated PI3K/AKT and p53 signaling by targeting AIFM3 reducing apoptosis and tissue death after a myocardial infarction | [125] | |
α-Mem 10% Exo-removed FBS | 1 | 72 h | Overexpression of miR-125b-5p. Ability to modify the direction of exosomes to ischemic tissue | [126] |
- Citation: Pulido-Escribano V, Torrecillas-Baena B, Camacho-Cardenosa M, Dorado G, Gálvez-Moreno MÁ, Casado-Díaz A. Role of hypoxia preconditioning in therapeutic potential of mesenchymal stem-cell-derived extracellular vesicles. World J Stem Cells 2022; 14(7): 453-472
- URL: https://www.wjgnet.com/1948-0210/full/v14/i7/453.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v14.i7.453